KAZA1
MCID: KLZ004
MIFTS: 41

Kala-Azar 1 (KAZA1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Kala-Azar 1

MalaCards integrated aliases for Kala-Azar 1:

Name: Kala-Azar 1 57
Kala-Azar, Susceptibility to, 1 57 13
Leishmaniasis 58 70
Leishmaniasis, Visceral, Susceptibility to, 1 57
Leishmaniasis, Visceral 1 57
Kaza1 57

Characteristics:

Orphanet epidemiological data:

58
leishmaniasis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Worldwide); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM® 57 608207
OMIM Phenotypic Series 57 PS608207
MESH via Orphanet 45 D007896
ICD10 via Orphanet 33 B55.0 B55.1 B55.2 more
UMLS via Orphanet 71 C0023281
Orphanet 58 ORPHA507
UMLS 70 C0023281

Summaries for Kala-Azar 1

MalaCards based summary : Kala-Azar 1, also known as kala-azar, susceptibility to, 1, is related to leishmaniasis and cutaneous leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kala-Azar 1 is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To). The drugs Lidocaine and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and bone, and related phenotypes are splenomegaly and hepatomegaly

More information from OMIM: 608207 PS608207

Related Diseases for Kala-Azar 1

Diseases in the Kala-Azar 1 family:

Kala-Azar 2 Kala-Azar 3

Diseases related to Kala-Azar 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 12.1
2 cutaneous leishmaniasis 11.9
3 mucocutaneous leishmaniasis 11.7
4 leishmaniasis, tegumentary 11.2
5 kala-azar 2 11.1
6 kala-azar 3 11.1
7 visceral leishmaniasis 11.0
8 chronic rhinitis 10.9
9 splenomegaly 10.9
10 pancytopenia 10.8
11 chagas disease 10.8
12 disease by infectious agent 10.7
13 hansen's disease 10.7
14 leprosy 3 10.7
15 immune deficiency disease 10.6
16 skin disease 10.6
17 human immunodeficiency virus type 1 10.6
18 acquired immunodeficiency syndrome 10.5
19 trypanosomiasis 10.5
20 cytokine deficiency 10.5
21 malaria 10.5
22 neutropenia 10.5
23 triiodothyronine receptor auxiliary protein 10.5
24 hemophagocytic lymphohistiocytosis 10.4
25 sleeping sickness 10.4
26 schistosoma mansoni infection, susceptibility/ 10.4
27 schistosomiasis 10.4
28 allergic disease 10.4
29 toxoplasmosis 10.4
30 bacterial infectious disease 10.4
31 thrombocytopenia 10.4
32 diarrhea 10.4
33 exanthem 10.3
34 lupus erythematosus 10.3
35 erysipeloid 10.3
36 glomerulonephritis 10.3
37 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
38 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.3
39 lepromatous leprosy 10.3
40 sporotrichosis 10.3
41 proteinuria, chronic benign 10.3
42 uveitis 10.3
43 systemic lupus erythematosus 10.3
44 filariasis 10.3
45 vasculitis 10.3
46 dermatitis 10.2
47 acute kidney failure 10.2
48 kidney disease 10.2
49 lymphopenia 10.2
50 alopecia 10.2

Graphical network of the top 20 diseases related to Kala-Azar 1:



Diseases related to Kala-Azar 1

Symptoms & Phenotypes for Kala-Azar 1

Human phenotypes related to Kala-Azar 1:

58 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 Very frequent (99-80%)
2 hepatomegaly 58 Very frequent (99-80%)
3 fatigue 58 Occasional (29-5%)
4 anemia 58 Frequent (79-30%)
5 elevated hepatic transaminase 58 Frequent (79-30%)
6 pallor 58 Frequent (79-30%)
7 thrombocytopenia 58 Occasional (29-5%)
8 skin ulcer 58 Very frequent (99-80%)
9 anorexia 58 Occasional (29-5%)
10 arthralgia 58 Frequent (79-30%)
11 weight loss 58 Frequent (79-30%)
12 abnormal bleeding 58 Very frequent (99-80%)
13 papule 58 Very frequent (99-80%)
14 hypoalbuminemia 58 Frequent (79-30%)
15 abnormal oral mucosa morphology 58 Very frequent (99-80%)
16 increased antibody level in blood 58 Frequent (79-30%)
17 lymphadenopathy 58 Very frequent (99-80%)
18 pancytopenia 58 Very frequent (99-80%)
19 leukopenia 58 Occasional (29-5%)
20 abnormal oral cavity morphology 58 Very frequent (99-80%)
21 recurrent fever 58 Very frequent (99-80%)
22 abnormal macrophage morphology 58 Very frequent (99-80%)
23 rhinitis 58 Very frequent (99-80%)
24 skin plaque 58 Very frequent (99-80%)
25 night sweats 58 Very frequent (99-80%)

Clinical features from OMIM®:

608207 (Updated 20-May-2021)

UMLS symptoms related to Kala-Azar 1:


fever; pruritus; exanthema

Drugs & Therapeutics for Kala-Azar 1

Drugs for Kala-Azar 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
3
deoxycholic acid Approved Phase 4 83-44-3 222528
4
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
5 Anesthetics Phase 4
6 Anti-Bacterial Agents Phase 4
7 Liposomal amphotericin B Phase 4
8 Amebicides Phase 4
9 Amphotericin B, deoxycholate drug combination Phase 4
10 Gastrointestinal Agents Phase 4
11
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
12
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
13
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
14
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
15
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
16
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
17
Tocopherol Approved, Investigational Phase 3 1406-66-2
18
Paromomycin Approved, Investigational Phase 3 7542-37-2, 1263-89-4 165580
19
Nitric Oxide Approved Phase 3 10102-43-9 145068
20
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 447043
21
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
22
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
23
Molgramostim Investigational Phase 3 99283-10-0
24 Tocotrienol Investigational Phase 3 6829-55-6
25 Antiparasitic Agents Phase 3
26 Antiprotozoal Agents Phase 3
27 Antifungal Agents Phase 3
28 Adjuvants, Immunologic Phase 2, Phase 3
29 Immunologic Factors Phase 3
30 interferons Phase 3
31 Vitamins Phase 3
32 Tocotrienols Phase 3
33 Tocopherols Phase 3
34 Pharmaceutical Solutions Phase 3
35 Antimony Sodium Gluconate Phase 3
36 Anthelmintics Phase 3
37 Vasodilator Agents Phase 3
38 Respiratory System Agents Phase 3
39 Anti-Asthmatic Agents Phase 3
40 Antioxidants Phase 3
41 Neurotransmitter Agents Phase 3
42 Protective Agents Phase 3
43 Endothelium-Dependent Relaxing Factors Phase 3
44 Bronchodilator Agents Phase 3
45 Hormone Antagonists Phase 3
46 Hormones Phase 3
47 Cytochrome P-450 Enzyme Inhibitors Phase 3
48
Miltefosine Approved, Investigational Phase 1, Phase 2 58066-85-6 3600
49
Coal tar Approved Phase 2 8007-45-2
50
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
3 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
4 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
5 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
6 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
7 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
8 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
9 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
10 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
11 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
12 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
13 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
14 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
15 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
16 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
17 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
18 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
19 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
20 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
21 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
22 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
23 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
24 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
25 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
26 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Completed NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
27 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
28 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
29 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
30 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
31 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
32 Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL) Completed NCT04340128 Phase 3 Meglumine antimoniate;Meglumine antimoniate
33 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
34 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
35 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
36 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Completed NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
37 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
38 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
39 Efficacy and Safety of Thermotherapy in Combination With Miltefosine Compared to Meglumine Antimoniate and Miltefosine Monotherapy for the Treatment of New World Cutaneous Leishmaniasis: A Phase III, Open Label, Multicenter Randomized Trial Recruiting NCT04515186 Phase 3 Meglumine Antimoniate;Miltefosine
40 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Active, not recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
41 Randomised, Open Label, Multicentre, Non-inferiority Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan Not yet recruiting NCT04268524 Phase 3
42 Treatment of Bolivian Mucosal Leishmaniasis With Miltefosine, Pentavalent Antimony or Liposomal Amphotericin B Not yet recruiting NCT04799236 Phase 3 Group 1: Miltefosine;Group 2: Pentavalent Antimony;Group 3: Liposomal amphotericin B
43 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
44 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
45 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
46 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
47 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
48 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
49 Treatment of Mucocutaneous Leishmaniasis With Miltefosine Completed NCT01050907 Phase 2 Miltefosine
50 Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru Completed NCT01032382 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)

Search NIH Clinical Center for Kala-Azar 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
miltefosine

Genetic Tests for Kala-Azar 1

Anatomical Context for Kala-Azar 1

MalaCards organs/tissues related to Kala-Azar 1:

40
Skin, T Cells, Bone, Bone Marrow, Liver, Spleen, Kidney

Publications for Kala-Azar 1

Articles related to Kala-Azar 1:

(show top 50) (show all 22575)
# Title Authors PMID Year
1
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. 57 61
23291585 2013
2
Genetic admixture in Brazilians exposed to infection with Leishmania chagasi. 57 61
19397557 2009
3
SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. 57 61
14523377 2004
4
A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. 57 61
14557985 2003
5
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 61 57
12618857 2003
6
The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. 61 57
12475635 2002
7
Clinical, epidemiological and climatic factors related to the occurrence of cutaneous leishmaniasis in an endemic area in northeastern Brazil. 61
32876165 2021
8
The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death. 61
33515743 2021
9
Rickettsial agents detected in the genus Psathyromyia (Diptera:Phlebotominae) from a Biosphere Reserve of Veracruz, Mexico. 61
33486127 2021
10
Natural biflavonoids as potential therapeutic agents against microbial diseases. 61
33493916 2021
11
Antileishmanial effect of silver nanoparticles: Green synthesis, characterization, in vivo and in vitro assessment. 61
33571836 2021
12
The effects of natural disasters on leishmaniases frequency: A global systematic review and meta-analysis. 61
33567321 2021
13
Spatiotemporal patterns of cutaneous leishmaniasis in the district upper and lower Dir, Khyber Pakhtunkhwa, Pakistan: A GIS-based spatial approaches. 61
33587943 2021
14
Identification of differential protein expression and putative drug target in metacyclic stage of Leishmania major and Leishmania tropica: A quantitative proteomics and computational view. 61
33581562 2021
15
In vitro antileishmanial potentialities of essential oils from Citrus limon and Pistacia lentiscus harvested in Tunisia. 61
33426571 2021
16
The host mTOR pathway and parasitic diseases pathogenesis. 61
33534053 2021
17
Investigations on the effects of anti-Leishmania major serum on the progression of Leishmania infantum infection in vivo and in vitro - implications of heterologous exposure to Leishmania spp. 61
33792813 2021
18
Unraveling the conformational dynamics of glycerol 3-phosphate dehydrogenase, a nicotinamide adenine dinucleotide-dependent enzyme of Leishmania mexicana. 61
32174264 2021
19
Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. 61
33370607 2021
20
Low Serum Levels of Selenium, Zinc, Iron, and Zinc/Copper Ratio in an Endemic Region of Cutaneous Leishmaniasis in Southwest Iran. 61
32607766 2021
21
Squamous cell carcinoma superimposed on mucosal leishmaniasis in an HIV-positive patient. 61
33570462 2021
22
Evaluating the efficacy and safety of vascular IPL for treatment of acute cutaneous leishmaniasis: a randomized controlled trial. 61
32681219 2021
23
Neutrophils and Visceral Leishmaniasis: Impact on innate immune response and cross-talks with macrophages and dendritic cells. 61
33345353 2021
24
Leishmaniasis in Cameroon: what is known and is done so far? A protocol for systematic review. 61
33811058 2021
25
Pediatric visceral leishmaniasis: a retrospective study to propose the diagnostic tests algorithm in southern Iran. 61
33576903 2021
26
Localized skin inflammation during cutaneous leishmaniasis drives a chronic, systemic IFN-γ signature. 61
33793565 2021
27
The global, regional, and national burden of leishmaniasis: An ecologic analysis from the Global Burden of Disease Study 1990-2017. 61
32822799 2021
28
Urine qPCR diagnoses over the entire clinical-immunological spectrum of human Leishmania (L.) infantum chagasi-infections in the Brazilian Amazon. 61
33333246 2021
29
Evaluation of protection induced by in vitro maturated BMDCs presenting CD8+ T cell stimulating peptides after a heterologous vaccination regimen in BALB/c model against Leishmania major. 61
33581108 2021
30
Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions. 61
33534106 2021
31
Prevalence and associated factors of asymptomatic leishmaniasis: a systematic review and meta-analysis. 61
33144197 2021
32
Spatiotemporal patterns and spatial risk factors for visceral leishmaniasis from 2007 to 2017 in Western and Central China: A modelling analysis. 61
33385656 2021
33
Meta-analysis of -308G > A polymorphism in TNFα gene and susceptibility to leishmaniasis. 61
33503580 2021
34
Prevalence of human visceral leishmaniasis in Iran: A systematic review and meta-analysis. 61
33388595 2021
35
Evolution of antigen-specific immune responses in cutaneous leishmaniasis patients. 61
33351204 2021
36
Lutzomyia longipalpis, Gone with the Wind and Other Variables. 61
32840741 2021
37
Species diversity and blood meal sources of phlebotomine sand flies (Diptera: Psychodidae) from Los Tuxtlas, Veracruz, Mexico. 61
33465351 2021
38
Investigation of Phlebotominae (Diptera: Psychodidae) Fauna, Seasonal Dynamics, and Natural Leishmania spp. Infection in Muğla, Southwest of Turkey. 61
33428877 2021
39
Epidemiological and pathological characteristics of Cutaneous Leishmaniasis from Baluchistan Province of Pakistan. 61
33353570 2021
40
Assessment of Euphorbia retusa and Pulicaria undulata activity against Leishmania major and Toxoplasma gondii. 61
33797536 2021
41
Odour of domestic dogs infected with Leishmania infantum is attractive to female but not male sand flies: Evidence for parasite manipulation. 61
33735302 2021
42
Alkyl-Resorcinol Derivatives as Inhibitors of GDP-Mannose Pyrophosphorylase with Antileishmanial Activities. 61
33799883 2021
43
Revisiting Pyrazolo[3,4-d]pyrimidine Nucleosides as Anti-Trypanosoma cruzi and Antileishmanial Agents. 61
33784107 2021
44
Six New Phenylpropanoid Derivatives from Chemically Converted Extract of Alpinia galanga (L.) and Their Antiparasitic Activities. 61
33801067 2021
45
Publication Trends in Neglected Tropical Diseases of Latin America and the Caribbean: A Bibliometric Analysis. 61
33802834 2021
46
Modelling Sand Fly Lutzomyia longipalpis Attraction to Host Odour: Synthetic Sex-Aggregation Pheromone Dominates the Response. 61
33804003 2021
47
Bio-guided isolation of anti-leishmanial natural products from Diospyros gracilescens L. (Ebenaceae). 61
33789661 2021
48
Expression in Escherichia coli, purification and kinetic characterization of LAPLm, a Leishmania major M17-aminopeptidase. 61
33775769 2021
49
Novel coumarin-isatin hybrids as potent antileishmanial agents: Synthesis, in silico and in vitro evaluations. 61
33799180 2021
50
LmjF.36.3850 a novel hypothetical Leishmania major protein contributes to the infection. 61
33764520 2021

Variations for Kala-Azar 1

Expression for Kala-Azar 1

Search GEO for disease gene expression data for Kala-Azar 1.

Pathways for Kala-Azar 1

GO Terms for Kala-Azar 1

Sources for Kala-Azar 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....